Ellavoz Impact Angel Network Invests in Orbican Systems, Inc.
ELLAVOZ IMPACT CAPITAL and its IMPACT ANGEL NETWORK have signed a term sheet for a $3 million SEED capital investment into Orbican Systems Inc. Orbican's patented platform technologies enable advanced precision medicine in cancer therapy. Dr. G Steven Bova, and Antti Koskenalho are founders of Orbican which will own IP and technology based on over $33 Million of grant funding and 30 years of research. This is the second startup company to have Dr. Bova and Robert H Hutchins, CEO of Ellavoz Impact Capital, as founders or early funders. Their previous being Biofortis, a bioinformatics company, which was sold to IQVIA (NYSE) in 2018.
“We are excited to support another Dr. Bova startup impact investment which will revolutionize personal cancer therapeutic navigation with new tools using immense data accumulated over a 35-year career of prostate cancer research.” According to Robert H Hutchins, CEO of Ellavoz.
ABOUT ORBICAN: Orbican was pioneered in Finland by physician scientist G. Steven Bova. Dr. Bova’s academic institutions have been Dartmouth (A.B., with distinction), Cornell (M.D., with honors, Pathology residency training), University of Virginia (Chief Resident in Urologic Surgery), Johns Hopkins (Research Scholar and on faculty in Urology, Pathology, Genetic Medicine, Health Sciences Informatics, and Oncology), Orbican's top flagship product is 3x3D, which includes a device (for patients undergoing robot assisted radical prostatectomy) and patented system for providing patients with intermediate or high-risk prostate cancer with lifelong advanced precision medicine service after their initial surgery or radiation therapy. Its Dovo product benefits patients through improving the quality of cancer genome profiling performed in hospital and commercial laboratories.
ABOUT ELLAVOZ IMPACT ANGEL NETWORK: The EIAN are UHNW families and partners of ELLAVOZ IMPACT CAPITAL who wish to directly invest in projects and companies that can return above market returns as well as develop significant value to society. Each investment is subject to thorough due diligence for the network. In addition to moonshot investments in life-changing healthcare technologies, EIC builds workforce affordable housing in underserved communities that qualify for the tax benefits of opportunity zone investment.